JERUSALEM – Teva Pharmaceutical Industries is teaming up with Intel Corporation to develop a wearable device and machine-learning platform for Huntington Disease.
“The aim of this important project is to provide continuous objective data on the impact of Huntington Disease on the patient, and, by extension, a clear understanding of the impact of treatment on patients’ quality of life,” said Michael Hayden, president of Teva Global R&D and chief scientific officer.
The current measurement of HD symptoms is largely based on physicians’ observations during an office visit. The technology being developed by Teva and Intel will provide a way to have continuous monitoring and could complement future clinical trials for HD.
Teva and Intel will deploy the technology platform in a sub-study within the ongoing Phase 2 Open-Pride HD Study. As part of this, patients will use a smartphone and smart watch equipped with sensors that will continuously measure their general functioning and movement. The data will be streamed to a cloud-based platform specifically developed by Intel to analyze data from wearable devices. Algorithms will translate the data into objective scores of motor symptom severity.
The study will begin in the next couple of months in the U.S. and Canada.
“Patients generate data based on their day-to-day experiences that can help in improving disease management—even something as simple as wearing a smart watch can add useful insight,” said Jason Waxman, Intel corporate vice president and general manager of the Datacenter Solutions Group, in a press release. “The complexity of analyzing these data streams requires a platform for machine learning, to help drive the pharmaceutical industry toward faster, better clinical trials, potentially leading to new treatments for patients.”